tyrosinase + gp100 + MART-1 + Montanide ISA 51 + interleukin-12 + aluminum hydroxide

This refers to a specific investigational peptide-based cancer vaccine regimen developed by the University of Southern California for the treatment of resected high-risk melanoma (Stages IIB-IV). The vaccine is a combination therapy consisting of three melanoma-associated peptide antigens—gp100(209-217), MART-1(26-35), and tyrosinase(368-376)—emulsified with the adjuvant Montanide ISA 51. This mixture is administered in conjunction with recombinant interleukin-12 (IL-12) that has been formulated with aluminum hydroxide (alum). In this specific formulation, the alum acts as a sustained-release vehicle for IL-12, prolonging its immunostimulatory effects at the injection site to enhance the recruitment and activation of T cells against the melanoma antigens. Clinical trial results indicated that this alum-containing combination was more effective at inducing immune responses than a similar regimen using GM-CSF, and these responses were associated with improved relapse-free survival.

Other names

alum adjuvant-University of Southern California-MelanomaPeptide Vaccine with IL-12 and AlumTyrosinase/gp100/MART-1 peptide vaccine with IL-12 and Alumgp100 + MART-1 + tyrosinase + Montanide ISA 51 + IL-12 + alum